Spike Protein News and Research

RSS

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

NVX-CoV2373, a recombinant nanoparticle vaccine developed by Novavax and manufactured at Emergent Biosolutions, was found to be well tolerated and immunogenic – inducing T-cell response and neutralization antibodies four-fold higher than the mean observed in hospitalized coronavirus disease (COVID-19) patients, shows a recent study available on the medRxiv* preprint server.

9 Aug 2020

Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19)

Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.

9 Aug 2020

Study: Drinking honeysuckle decoction accelerates the negative conversion of COVID-19 patients

In a new study in Cell Discovery, Chen-Yu Zhang's group at Nanjing University and two other groups from Wuhan Institute of Virology and the Second Hospital of Nanjing present a novel finding that absorbed miRNA MIR2911 in honeysuckle decoction (HD) can directly target SARS-CoV-2 genes and inhibit viral replication. Drinking of HD accelerate the negative conversion of COVID-19 patients.

7 Aug 2020

Carefully engineered spike protein can help develop COVID-19 vaccine

The experimental vaccine against SARS-CoV-2 that was the first to enter human trials in the United States has been shown to elicit neutralizing antibodies and a helpful T-cell response with the aid of a carefully engineered spike protein that mimics the infection-spreading part of the virus.

6 Aug 2020

Study reveals changes in transmissibility of SARS-CoV-2 due to D614G spike mutation

A recent research endeavor from the UK, currently available on the medRxiv preprint server, indicates that spike 614G variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) increases in frequency relative to 614D variant in a selective advantage manner – but without higher coronavirus disease (COVID-19) mortality rates.

5 Aug 2020

A SARS-CoV-2 assay using plant proteins

Researchers in South Africa have developed a serological assay that readily detects antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using recombinant viral proteins produced in plants.

5 Aug 2020

NIH-Moderna investigational vaccine protects mice from infection with SARS-CoV-2

The investigational vaccine known as mRNA-1273 protected mice from infection with SARS-CoV-2, the virus that causes COVID-19, according to research published today in Nature.

5 Aug 2020

Evidence for antibody longevity in COVID-19 patients

A study led by researchers at the University of Toronto, Canada, has found evidence that immunoglobulin G (IgG) antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are sustained for at least three months.

5 Aug 2020

New serological test for COVID-19 helps determine herd immunity, vaccine efficacy

New COVID-19 test evaluates herd immunity and vaccine efficacy with high accuracy.

5 Aug 2020

Avidity of binding responsible for cross-neutralization of SARS-CoV-1 and SARS-CoV-2

In a new study published on the preprint server bioRxiv researchers characterized the crystal structure of the antibody-SARS-CoV-2 RBD complex in an attempt to find the epitope and the mechanism that enables cross-neutralization.

5 Aug 2020

Embryos are susceptible to COVID-19 if mothers get sick, indicates study

Genes that are thought to play a role in how the SARS-CoV-2 virus infects our cells have been found to be active in embryos as early as during the second week of pregnancy, say scientists at the University of Cambridge and the California Institute of Technology (Caltech).

5 Aug 2020

Regeneron's COVID-19 antibody-drug cocktail treats SARS-CoV-2 virus in animals

Now, Regeneron Pharmaceuticals says its COVID-19 antibody-drug cocktail under development prevented and treated the disease in monkeys and hamsters, showing promise that it may work in humans.

5 Aug 2020

Study: "Memory" T cells that recognize common cold coronaviruses also recognize SARS-CoV-2

Your immune system's "memory" T cells keep track of the viruses they have seen before. This immune cell memory gives the cells a headstart in recognizing and fighting off repeat invaders.

5 Aug 2020

Picomolar inhibitors to SARS-CoV-2 proteins

Now, a new study published on the preprint server bioRxiv in August 2020 reports the development of mini-inhibitors based on computational design, that are suitable for such topical use.

4 Aug 2020

Novel mutation identified in SARS-CoV-2 spike protein from Sweden

Researchers from Sweden and Brazil have identified a novel mutation in a strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) obtained from a patient in Stockholm, Sweden, in late April.

4 Aug 2020

Regeneron antibody cocktail shows promise as potential COVID-19 treatment

Researchers in the U.S. have shown both preventive and treatment effects of an antibody cocktail in animal models of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the agent that causes coronavirus disease 2019 (COVID-19).

4 Aug 2020

Study shows high SARS-CoV-2 seroprevalence, but low death rate in Malawi's health care workers

A study by researchers from Malawi and United Kingdom reveals a significant discrepancy between predicted coronavirus disease (COVID-19) mortality in the observed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence rates in health care workers and reported deaths in urban Malawi in southeastern Africa, indicating early exposure, but a slow progression of the outbreak. Their findings are currently available on the medRxiv preprint server.

3 Aug 2020

SARS-CoV-2 lured away and trapped by a new decoy version of ACE2

Researchers in the United States and Canada have engineered affinity-optimized “receptor traps” that prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from binding to and infecting cells.

3 Aug 2020

Novel short ACE2 isoform may influence SARS-CoV-2 susceptibility

A study led by researchers at the University of Southampton, UK, has identified a novel short isoform of the full-length receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses to gain entry to host cells.

3 Aug 2020

Stabilized prefusion spike vaccine candidate induces powerful immune response

A new research paper by scientists at Janssen Vaccines & Prevention BV, in the Netherlands and published on the preprint server bioRxiv* is based on the assumption that an effective vaccine against these infections will induce neutralizing antibodies and an immune response favoring Th1 immunity.

3 Aug 2020